BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 3601235)

  • 1. Cardiac vagal action and plasma levels of neuropeptide Y following intravenous injection in the dog.
    Potter EK
    Neurosci Lett; 1987 Jun; 77(2):243-7. PubMed ID: 3601235
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Peptide YY reduces effects of sympathetic nerves and neuropeptide Y on cardiac vagal action.
    Potter EK; McCloskey DI
    Peptides; 1991; 12(4):805-8. PubMed ID: 1788144
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the inhibitory roles of neuropeptide Y and galanin on cardiac vagal action in the dog.
    Moriarty M; Gibbins IL; Potter EK; McCloskey DI
    Neurosci Lett; 1992 May; 139(2):275-9. PubMed ID: 1376882
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Desensitization by neuropeptide Y of effects of sympathetic stimulation on cardiac vagal action in anaesthetised dogs.
    Moriarty M; Potter EK; McCloskey DI
    J Auton Nerv Syst; 1993 Oct; 45(1):21-8. PubMed ID: 8227962
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Guanethidine blocks neuropeptide-Y-like inhibitory action of sympathetic nerves on cardiac vagus.
    Potter EK
    J Auton Nerv Syst; 1987 Nov; 21(1):87-90. PubMed ID: 3440821
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Presynaptic inhibition of cardiac vagal postganglionic nerves by neuropeptide Y.
    Potter E
    Neurosci Lett; 1987 Dec; 83(1-2):101-6. PubMed ID: 3441289
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of cardiac vagal action by galanin but not neuropeptide Y in the brush-tailed possum Trichosurus vulpecula.
    Courtice GP; Potter EK; McCloskey DI
    J Physiol; 1993 Feb; 461():379-86. PubMed ID: 7688807
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacological separation of cardio-accelerator and vagal inhibitory capacities of sympathetic nerves.
    Moriarty M; Potter EK; McCloskey DI
    J Auton Nerv Syst; 1993 Apr; 43(1):7-16. PubMed ID: 8315212
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Attenuation of long-lasting effects of sympathetic stimulation after repeated stimulation.
    Hall GT; Gardner TD; Potter EK
    Circ Res; 1990 Jul; 67(1):193-8. PubMed ID: 2364490
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The cardiac sympathetic co-transmitter galanin reduces acetylcholine release and vagal bradycardia: implications for neural control of cardiac excitability.
    Herring N; Cranley J; Lokale MN; Li D; Shanks J; Alston EN; Girard BM; Carter E; Parsons RL; Habecker BA; Paterson DJ
    J Mol Cell Cardiol; 2012 Mar; 52(3):667-76. PubMed ID: 22172449
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of arterial baroreceptor and chemoreceptor reflex responses by neuropeptide Y in anaesthetised dogs.
    Moriarty M; Potter EK; McCloskey DI
    J Auton Nerv Syst; 1992 Jul; 39(3):169-79. PubMed ID: 1527350
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sympathetic-parasympathetic interactions at the heart, possibly involving neuropeptide Y, in anaesthetized dogs.
    Revington ML; McCloskey DI
    J Physiol; 1990 Sep; 428():359-70. PubMed ID: 2231416
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prolonged inhibition of cardiac vagal action following sympathetic stimulation and galanin in anaesthetized cats.
    Revington M; Potter EK; McCloskey DI
    J Physiol; 1990 Dec; 431():495-503. PubMed ID: 1712845
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antagonism of pre- and postjunctional responses to neuropeptide Y and sympathetic stimulation by D-myo-inositol-1,2,6-trisphosphate in the anaesthetised dog.
    Potter EK; Edvinsson L; Gustafsson T
    Eur J Pharmacol; 1992 Oct; 221(2-3):307-14. PubMed ID: 1426007
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sympathetic-parasympathetic interactions at the heart in the anaesthetised rat.
    Smith-White MA; Wallace D; Potter EK
    J Auton Nerv Syst; 1999 Feb; 75(2-3):171-5. PubMed ID: 10189119
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neuropeptide Y reduces acetylcholine release and vagal bradycardia via a Y2 receptor-mediated, protein kinase C-dependent pathway.
    Herring N; Lokale MN; Danson EJ; Heaton DA; Paterson DJ
    J Mol Cell Cardiol; 2008 Mar; 44(3):477-85. PubMed ID: 17996892
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Central neuropeptide Y enhances bile secretion through vagal and muscarinic but not nitric oxide pathways in rats.
    Yoneda M; Tamasawa N; Takebe K; Tamori K; Yokohama S; Sato Y; Nakamura K; Makino I; Taché Y
    Peptides; 1995; 16(4):727-32. PubMed ID: 7479309
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dependence of hypotensive effect of neuropeptide-Y 18-36 fragment on intact vagus nerves.
    Potter EK; Persico M; Mitchell L; de Pietra MG; Loughnan M; Shine J; McCloskey DI
    J Auton Nerv Syst; 1992 Mar; 37(3):155-62. PubMed ID: 1587993
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Pro34]neuropeptide Y selectively identifies postjunctional-mediated actions of neuropeptide Y in vivo in rats and dogs.
    Potter EK; Fuhlendorff J; Schwartz TW
    Eur J Pharmacol; 1991 Jan; 193(1):15-9. PubMed ID: 2050189
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neuropeptide Y is a prejunctional inhibitor of vagal but not sympathetic inotropic responses in guinea-pig isolated left atria.
    Serone AP; Angus JA
    Br J Pharmacol; 1999 May; 127(2):383-90. PubMed ID: 10385237
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.